Non-Malaysian citizens are subject to 6% SST, to be verified and paid at the counter before screening.
The EBV (Epstein-Barr Virus) test is an important screening tool for nasopharyngeal carcinoma (NPC). EBV is closely linked with NPC development. Testing EBV antibodies or EBV DNA helps evaluate an individual's cancer risk.
EBV antibody tests are commonly used for screening, while EBV DNA tests provide higher sensitivity and specificity for diagnosis and monitoring.
A venous blood sample is collected to test for EBV antibodies (e.g., VCA-IgA, EA-IgA) or EBV DNA. Results should always be interpreted with imaging (nasopharyngoscopy, MRI, CT) and clinical evaluation.
Q1: Does EBV infection always lead to nasopharyngeal carcinoma?
A: No. While EBV infection is common, only a small portion of high-risk individuals develop NPC.
Q2: What is the difference between EBV antibody and EBV DNA testing?
A: Antibody testing is often used for mass screening, while DNA testing is more suitable for diagnosis and follow-up.
Q3: Who should undergo regular EBV testing?
A: Individuals with family history or living in high-risk regions should consider regular screening under medical advice.